Anthropometry in 5- to 9-Year-Old Greenlandic and Ukrainian Children in Relation to Prenatal Exposure to Perfluorinated Alkyl Substances
Overview
Authors
Affiliations
Background: In some animal studies, perfluorinated alkyl substances are suggested to induce weight gain. Human epidemiological studies investigating these associations are sparse.
Objective: We examined pregnancy serum concentrations of perfluorooctanoate (PFOA) and perfluorooctane sulfonate (PFOS) and the prevalence of offspring overweight (> 1 SD) and waist-to-height ratio (WHtR) > 0.5 at 5-9 years of age.
Methods: Sera from 1,022 pregnant women enrolled in the INUENDO cohort (2002-2004) from Greenland and Kharkiv (Ukraine) were analyzed for PFOA and PFOS using liquid chromatography-tandem mass spectrometry. Relative risks (RR) of being overweight and having WHtR > 0.5 in relation to continuous and categorized (tertiles) PFOA and PFOS were calculated at follow-up (2010-2012) using generalized linear models.
Results: Pooled PFOA median (range) was 1.3 (0.2-5.1) and PFOS median (range) was 10.8 (0.8-73.0) ng/mL. For each natural logarithm-unit (ln-unit) increase of pregnancy PFOA, the adjusted RR of offspring overweight was 1.11 [95% confidence interval (CI): 0.82, 1.53] in Greenlandic children. In Ukrainian children, the adjusted RR of offspring overweight was 1.02 (95% CI: 0.72, 1.44) for each ln-unit increase of pregnancy PFOA. Prenatal exposure to PFOS was not associated with overweight in country-specific or pooled analysis. The adjusted RR of having WHtR > 0.5 for each ln-unit increase of prenatal exposure to PFOA was 1.30 (95% CI: 0.97, 1.74) in the pooled analysis. For 1-ln-unit increase of prenatal exposure to PFOS, the adjusted RR of having a WHtR > 0.5 was 1.38 (95% CI: 1.05, 1.82) in the pooled analysis.
Conclusions: The results indicate that prenatal PFOA and PFOS exposures may be associated with child waist-to-height ratio > 0.5. Prenatal PFOA and PFOS exposures were not associated with overweight.
Pezeshki H, Rajabi S, Hashemi M, Moradalizadeh S, Nasab H Heliyon. 2025; 11(4):e42782.
PMID: 40066031 PMC: 11891678. DOI: 10.1016/j.heliyon.2025.e42782.
Hall A, Braun J Am J Lifestyle Med. 2025; 19(2):211-229.
PMID: 39981556 PMC: 11836584. DOI: 10.1177/15598276231162802.
Hidden link between endocrine-disrupting chemicals and pediatric obesity.
Shin M, Kim S Clin Exp Pediatr. 2024; 68(3):199-222.
PMID: 39608365 PMC: 11884955. DOI: 10.3345/cep.2024.00556.
Key recommendations and research priorities of the 2021 AMAP human health assessment.
Khoury C, Weihe P Int J Circumpolar Health. 2024; 83(1):2408057.
PMID: 39360677 PMC: 11451291. DOI: 10.1080/22423982.2024.2408057.
Lohmann R, Abass K, Bonefeld-Jorgensen E, Bossi R, Dietz R, Ferguson S Sci Total Environ. 2024; 954:176274.
PMID: 39304148 PMC: 11567803. DOI: 10.1016/j.scitotenv.2024.176274.